CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

DuvelisibWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2211 Self-Compassion for Chronic Pain Virtual Group Treatment Program Wiki 1.00
drug1795 Peripheral blood draw Wiki 0.71
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D059350 Chronic Pain NIH 0.41

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012532 Chronic pain HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Pilot Study of Duvelisib to Combat COVID-19

The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. Based on preclinical data from this institution and others, the investigators hypothesize that PI3K inhibition with duvelisib could potentially quell aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, thereby improving patient outcomes.

NCT04372602 COVID-19 Drug: Duvelisib Procedure: Peripheral blood draw Drug: Placebo

Primary Outcomes

Measure: Overall survival

Time: Through 28 days

Secondary Outcomes

Measure: Length of hospital stay

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Length of ICU stay

Time: Through completion of follow-up (estimated to be 7 months)

Description: -For those on a ventilator at the time of randomization

Measure: Duration of ventilator use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration of vasopressors use

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Duration on renal replacement therapy

Time: Through completion of follow-up (estimated to be 7 months)

Description: -Defined as increase in viral load of >0.5 log on two consecutive days, or >1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing

Measure: Viral kinetics as measured by virologic failure

Time: Through completion of follow-up (estimated to be 7 months)

Measure: Number of adverse events as measured by CTCAE v. 5.0

Time: Through completion of follow-up (estimated to be 7 months)

No related HPO nodes (Using clinical trials)